A venture capital fund founded in 2015 and based in China closed its second fund at ¥100M that again focuses on opportunities in China. The firm invests in early-stage life science ventures from Seed to Series A. Typical initial size of investment ranges from $500k-1M USD.

The firm will consider medical devices especially minimally invasive medical devices, and diagnostics. Within medical devices, the fund is interested in 510k and software-enabled devices and looks at the in-development phase (must include proof of concept). Particularly, the firm is interested in devices related to digital technology such as artificial intelligence. Within diagnostics, the firm is interested in in-vitro diagnostics that are in-development. The main indication areas of interest are heart disease, infectious disease, chronic disease, and rehabilitation.

The firm prefers to work with a management team with established industry partners. The fund also prefers the CEO to have expertise in the respective life science fields. The fund is open to both leading and co-investing and will not require board seating. Although it has a China focus, the fund has supporting partners who are able to work with offshore companies that are interested in attaining proof of concept in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 and is headquartered in the USA. The firm currently manages 3 funds, and also has an advisory business that is solely dedicated for companies trying to enter the Asian market. The firm has a focus on early-stage investments (pre-Series A to Series B) and has portfolio companies spread over the USA. The firm’s initial investment size varies, but typically falls under the $250K – 2.5M range and is dedicated to follow-on financings of existing portfolio companies. The firm invests only in USA and Canada.

Within life sciences/healthcare, the firm is most interested in medical devices and smart manufacturing in life sciences, and is much more selective when it comes to biotech or therapeutics investments. Most importantly, the firm is focused on assessing the company’s patent status and the degree of novelty. While the firm is agnostic to stage of development, ideally the companies should have a working prototype and significant key data that validates the high potential of their technology. In terms of different types of technologies or diseases areas/indications, the firm is opportunistic.

The firm has no specific management team requirements, but considers patent strategy key in reviewing potential investments. Companies should have key patents issued or a clear strategy on improving their IP portfolio. The firm has great expertise in helping USA/Canada-based companies enter Asian markets (i.e. greater China) and extend their IP coverage. The firm can act as either lead or co-investor and will seek a board seat if they come in as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2014 and based in China. The firm currently holds ¥3B in assets under management. Historically, the firm focused on investing only in China. However, the current fund of $300M USD is focused on opportunities in the United States. The firm invests in early-stage life science ventures from Seed to Series B. Typical initial size of investment ranges from $100k-5M USD.

The firm will consider cost-effective therapeutics and diagnostics that reach urgent and unmet clinical needs. Within therapeutics, the firm is interested in cell & gene therapy, gene editing, and organoids, and looks at pre-clinical to Phase III. Within diagnostics, the firm is open to all types of technologies and phases of development.

With an overarching focus on the aging population, the firm is interested in technologies that can improve the quality and longevity of life. The main indication areas of interest are neurological pathways, CNS, and chronic and acute pain management.

The firm does not have any requirements of the management team. Further down the road, the firm is able to support companies that are interested in entering the China market. However, having a China angle is not necessary for investment. The firm intends to act as a co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading healthcare investment firm, with multi-billion in assets under management invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. The firm seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. The firm’s team of over 100 professionals is based in USA, Asia, the Middle East, and other key global markets.

The firm invests in all modalities and indications across therapeutics, devices, diagnostics, and digital health, and have no specific preference for technology type.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established investment funding arm of a USA-based health system, one of the largest non-profit health systems in the USA is actively seeking new partnering opportunities. The firm’s objectives include fostering the commercialization of internal ideas as well as external innovation. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.

The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the firm’s strategic position in the future. Areas of interest include improving the ratings and member retention in our Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.

The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A $1.2B AUM Seed through Series B venture firm based in the US typically invests between $500K to $20M. The firm focuses on two thematic areas – healthcare and enterprise SaaS. Within healthcare, the firm will invest in digital health, therapeutics, diagnostics and software-enabled medical devices. While somewhat flexible in stage, the firm prefers to have some POC for companies they invest in, such as some in vivo data, at least one hit for drug discovery, and a viable product/prototype for digital health and medical devices. The firm invests primarily in the US, but will invest in Canada as well.

Within healthcare, the firm invests in transformational technologies in all sectors. In therapeutics, the firm has an interest in cell & gene therapy and tissue engineering, but will invest in any modality if the technology is first-in-class. For small molecules or biologics, the firm does not invest in single assets. When investing in medical devices, the firm looks for those where software is a key component of the device. The firm invests in diagnostics and digital health as well, interested in technologies such as AI/ML technologies, drug discovery models, tech enabled services and data infrastructure, among others.

For later stage companies, the firm has no specific requirements. For seed stage companies, the firm is an active investor, and leads in most of their investments, taking a board seat. The firm is interested in companies with strong management teams, having strong expertise in the industry in which the startup is based.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with USA and Europe offices is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tend to stray away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.